Literature DB >> 1345787

Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.

T Nishimura1, Y Nakamura, Y Takeuchi, Y Tokuda, M Iwasawa, A Kawasaki, K Okumura, S Habu.   

Abstract

We developed a culture system for the rapid generation of CD4+ T cells that have both helper and killer functions. CD4+ T cells isolated from human PBL did not proliferate or develop significant cytotoxicity when treated with rIL-2 because of the lack of p75 IL-2R expression. However, culture of isolated CD4+ T cells with immobilized anti-CD3 mAb plus rIL-2 resulted in a marked proliferation (500-fold increase in 14 days) of CD4+ T cells. The proliferating CD4+ T cells produced IL-2 (92 U/ml) and showed strong cytotoxicity against OKT3 hybridoma cells and Daudi, K562, and U937 tumor cells in an anti-CD3 mAb-dependent manner. The CD4+ T cells contained significant amounts of cytolytic granule-related proteins such as serine esterase and perforin. Activated CD4+ helper/killer cells can be generated from both healthy donors and tumor patients and can be propagated in vitro for 14 to 35 days by biweekly restimulation with immobilized anti-CD3 mAb plus rIL-2. This culture yielded about 20,000-fold increase in cell number after a 21-day culture. Bispecific antibody containing anti-CD3 and anti-glioma Fab components enhanced the cytotoxicity of activated CD4+ helper/killer cells against IMR32 glioma cells. Moreover, the activated CD4+ helper/killer cells showed both helper and antitumor activity in vivo and prevented growth of anti-CD3 hybridoma cells in nude mice whether or not IL-2 was administered. These results indicate that anti-CD3 mAb plus IL-2-activated CD4+ helper/killer cells may provide an effective strategy for adoptive tumor immunotherapy of cancer.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1345787

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Eradication of metastatic tumour cells from lymph nodes by local administration of anti-CD3 antibody.

Authors:  Y Dohi; S Sunada; M Aoki; A Moriguchi; M Okabayashi; M Miyata; H Matsuda
Journal:  Cancer Immunol Immunother       Date:  1993-06       Impact factor: 6.968

2.  Characterization of monoclonal antibodies specific for equine homologues of CD3 and CD5.

Authors:  M Blanchard-Channell; P F Moore; J L Stott
Journal:  Immunology       Date:  1994-08       Impact factor: 7.397

3.  Activated CD4+ T cells preferentially take up lipid microspheres, but resting cells do not.

Authors:  K Suzuki
Journal:  Clin Exp Immunol       Date:  1995-03       Impact factor: 4.330

4.  Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies.

Authors:  Ian M Zitron; Archana Thakur; Oxana Norkina; Geoffrey R Barger; Lawrence G Lum; Sandeep Mittal
Journal:  BMC Cancer       Date:  2013-02-22       Impact factor: 4.430

5.  Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo.

Authors:  T Nishimura; K Iwakabe; M Sekimoto; Y Ohmi; T Yahata; M Nakui; T Sato; S Habu; H Tashiro; M Sato; A Ohta
Journal:  J Exp Med       Date:  1999-09-06       Impact factor: 14.307

6.  Large-scale culture system of human CD4+ helper/killer T cells for the application to adoptive tumour immunotherapy.

Authors:  Y Nakamura; Y Tokuda; M Iwasawa; H Tsukamoto; M Kidokoro; N Kobayashi; S Kato; T Mitomi; S Habu; T Nishimura
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

7.  Tumour growth inhibition in mice by glycosylated recombinant human lymphotoxin: analysis of tumour-regional mononuclear cells involved with its action.

Authors:  I Funahashi; H Watanabe; T Abo; K Indo; H Miyaji
Journal:  Br J Cancer       Date:  1993-03       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.